Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076336 · ClinicalTrials.gov registry record · Phase 3
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
NCT00076336 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 232 participants.
The verdict
NCT00076336, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
Study Summary
This research study was conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) versus Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the treatment of Hepatitis B infection. The results for patients taking LdT will be compared to results for patients taking lamivudine.
Interventions
- DRUG Placebo
- DRUG Lamivudine
- DRUG Telbivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2003-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076336
The ClinicalTrials.gov registry entry for NCT00076336 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00076336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00076336 about?
NCT00076336 is a clinical study titled "Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis". This research study was conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) versus Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the treatment of Hepatitis B infection. The results for patients taking LdT...
What is the current status of trial NCT00076336?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2003-12.
What interventions are being tested in trial NCT00076336?
The interventions under investigation include: Placebo (DRUG), Lamivudine (DRUG), Telbivudine (DRUG).
Who is sponsoring clinical trial NCT00076336?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.